New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
GLP-1–Based Therapies: The Dilemma of<br />
Uncertainty<br />
Gastroenterology <strong>2011</strong>; 141:20-23<br />
• The accompanying editorial states “…more reliable studies<br />
must be performed. Until then, the questions about the<br />
potential link between GLP-1–based therapies and<br />
pancreatitis and tumorigenesis remain open. The fact that<br />
GLP-1–based therapies have no record of lowering clinical<br />
endpoints (ie, mortality, stroke, myocardial infarction)<br />
does not inspire confidence and more informative<br />
prospective randomized trials with such patient-relevant<br />
clinical endpoints are urgently required.”<br />
• “For the sake of patients, history will hopefully not repeat<br />
itself in the case of GLP-1–based drugs. Two thoughts<br />
remain: primum non nocere and “vigilance equals<br />
avoidance.”<br />
Dabigatran- Pradaxa<br />
by Boehringer Ingelheim<br />
Wayne Weart<br />
<strong>New</strong> <strong>Drug</strong> <strong>Update</strong> Part I